Pau

France

45 total trials 23 recruiting

Filter these 45 trials by phase, condition, sponsor and more.

Open in Search →

TRAnexamic Acid for Preventing blood loss following a cesarean delivery in women with placenta pREVIA: a multicenter randomised, double blin … Recruiting

2024-515276-12-00 5 2020-07-01 Postpartum Hemorrhage
DAPAgliflozine to attenuate cardiac RemOdeling afTEr aCuTe myOcardial infarction Ended recruitment

2024-511882-13-01 5 2024-11-19 Cardiac failure
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended recruitment

2023-509190-23-00 5 2024-09-03 Atherosclerotic Cardiovascular Disease Elevated lp(a)
PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed … Ended recruitment

2023-505972-32-00 5 2024-02-26 locally advanced anal squamous cell carcinoma
PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patien … Ended recruitment

2022-501217-31-00 10 2023-03-09 Hepatocellular carcinoma
Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence Ended recruitment

2024-514480-26-00 4 2022-10-12 Post-menopausal women with localized luminal A breast cancer and consi
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended recruitment

2024-510735-21-00 5 2021-11-26 Atherosclerotic cardiovascular disease (ASCVD)
Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab Ended recruitment

2024-516543-26-00 5 2021-07-23 Type 1 Diabetes Mellitus
Encorafenib in combination with Binimetinib in Patients with BRAFV600E mutant metastatic Lung Cancer Ended recruitment

2024-515944-22-00 4 2021-01-19 BRAFV600E-mutant metastatic Non-small Cell Lung Cancer
Methotrexate and Metformin in rheumatoid arthritis patients. Ended recruitment

2024-511033-35-00 4 2020-12-03 rheumatoid arthritis (RA)
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended recruitment

2023-510390-33-00 5 2020-10-23 HER2-negative breast cancer patients with high relapse risk after stan
Study comparing two standard treatments as initial metastatic treatment among patients with visceral metastasis of ER+ HER2- breast cancer, … Ended recruitment

2024-513005-31-00 5 2020-06-11 Patients with untreated metastatic Estrogen Receptor positive (ER+), H
The TARGET BP I Ended recruitment

2024-512525-83-00 5 2020-01-07 Hypertension
IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting Ended recruitment

2024-517489-41-00 5 2017-03-27 High-risk stage III colon cancer
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended recruitment

2024-510704-37-00 5 2017-03-22 ER+/HER2- metastatic breast cancer
IFCT-1802 SAVIMMUNE: Immunotherapy in Patient With Poor General Condition Ended

2024-515943-44-00 4 2020-10-14 Non small cell lung cancer
Phase 3 Study of Pembrolizumab with or without Maintenance Olaparib in First-Line Metastatic Squamous NSCLC Ended

2023-508449-41-00 5 2019-06-26 Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLC Ended

2023-509774-40-00 5 2019-06-25 Stage IV lung cancer condition
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok
Trial comparing the continuation of nivolumab and ipilimumab (doublet immunotherapy) to observation after a first 6 months treatment by nivo … Ended

2024-514586-20-01 5 2018-05-02 Non small cell lung cancer
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Can … Ended

2024-517856-36-00 5 2015-03-09 Completely resected primary stage IB (≥ 4cm), II and IIIA non-small ce

Showing 25–45 of 45 trials